Taurursodiol

CHEMBL272427 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

499.7 g/mol

LogP

3.6

Phase

4

Taurursodiol (sodium phenylbutyrate/ursodoxicoltaurine, also known as AMX0035) is a fixed-dose combination product that modulates endoplasmic reticulum stress and mitochondrial dysfunction, reducing neuronal and motor neuron apoptosis. It is approved for the treatment of amyotrophic lateral sclerosis (ALS) and is under investigation for neurodegenerative diseases. By targeting two complementary pathways of cell death, it offers a novel approach to neuroprotection.

Moleküler Ağırlık

499,7000 g/mol

LogP

3,60

TPSA

132,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Asthma Multiple Sclerosis Obesity Type 2 Diabetes Hypertension

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

InChI

InChI=1S/C26H45NO6S/c1-16(4-7-23(30)27-12-13-34(31,32)33)19-5-6-20-24-21(9-11-26(19,20)3)25(2)10-8-18(28)14-17(25)15-22(24)29/h16-22,24,28-29H,4-15H2,1-3H3,(H,27,30)(H,31,32,33)/t16-,17+,18-,19-,20+,21+,22+,24+,25+,26-/m1/s1

Molecular Formula

C26H45NO6S

HBD / HBA

4 / 6

Döndürülebilir Bağlar

7

Ağır Atomlar

34

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Taurursodiol (sodium phenylbutyrate/ursodoxicoltaurine, also known as AMX0035) is a fixed-dose combination product that modulates endoplasmic reticulum stress and mitochondrial dysfunction, reducing neuronal and motor neuron apoptosis. It is approved for the treatment of amyotrophic lateral sclerosis (ALS) and is under investigation for neurodegenerative diseases. By targeting two complementary pathways of cell death, it offers a novel approach to neuroprotection.

Yes, Taurursodiol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL272427. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9848818. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Taurursodiol PillFYI'da

Yapı

Hızlı Veriler

Formül: C26H45NO6S

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.